Literature DB >> 8419644

Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.

L J Chang1, E McNulty, M Martin.   

Abstract

The human immunodeficiency virus (HIV) type 1 long terminal repeat (LTR) contains binding sites for nuclear factor kappa B (NF-kappa B) and the constitutively expressed transcription factor Sp1, both of which are highly conserved in HIV and simian immunodeficiency virus isolates. To delineate the effects of these motifs on the replicative capacity of HIV and to explore the possibility of extending the virus host range, known heterologous enhancer/promoters were inserted into the HIV-1 LTR in place of the NF-kappa B and Sp1 binding sites. The effects of these substitutions on viral replication in transfected HeLa cells and on HIV infection of human peripheral blood lymphocytes or continuous T-leukemia cell lines were evaluated. HIVs in which the NF-kappa B/Sp1 enhancer plus the downstream TATA element were replaced with heterologous enhancer/promoters were also constructed. Viruses containing the human cytomegalovirus immediate-early enhancer exhibited infectious kinetics similar to that of wild-type HIV in activated human peripheral blood lymphocytes and AA2 cells but replicated less efficiently in H9 and CEM cells. These studies indicate that heterologous enhancer elements are capable of restoring Tat responsiveness to the HIV LTR in the context of directing reporter gene expression as well as in the production of infectious progeny virions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419644      PMCID: PMC237426     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase.

Authors:  L J Chang; R C Hirsch; D Ganem; H E Varmus
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

Review 2.  Regulation of HIV-1 gene expression.

Authors:  W C Greene
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

3.  Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.

Authors:  C Southgate; M L Zapp; M R Green
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Sequencing products of the polymerase chain reaction directly, without purification.

Authors:  S J Meltzer; S M Mane; P K Wood; L Johnson; S W Needleman
Journal:  Biotechniques       Date:  1990-02       Impact factor: 1.993

6.  The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity.

Authors:  J Leonard; C Parrott; A J Buckler-White; W Turner; E K Ross; M A Martin; A B Rabson
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

7.  Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer.

Authors:  L Clark; J R Matthews; R T Hay
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1.

Authors:  K A Jones; J T Kadonaga; P A Luciw; R Tjian
Journal:  Science       Date:  1986-05-09       Impact factor: 47.728

9.  Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation.

Authors:  M F Laspia; A P Rice; M B Mathews
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

10.  NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation.

Authors:  L C Sambucetti; J M Cherrington; G W Wilkinson; E S Mocarski
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

View more
  18 in total

1.  New way of regulating alternative splicing in retroviruses: the promoter makes a difference.

Authors:  Jens Bohne; Axel Schambach; Daniela Zychlinski
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

2.  CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.

Authors:  C Suñé; T Hayashi; Y Liu; W S Lane; R A Young; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

4.  Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex.

Authors:  F Kashanchi; S N Khleif; J F Duvall; M R Sadaie; M F Radonovich; M Cho; M A Martin; S Y Chen; R Weinmann; J N Brady
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.

Authors:  Wu Ou; Michael P Marino; Akiko Suzuki; Bharat Joshi; Syed R Husain; Andrea Maisner; Evanthia Galanis; Raj K Puri; Jakob Reiser
Journal:  Hum Gene Ther Methods       Date:  2012-05-21       Impact factor: 2.396

6.  Construction and in vitro characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses.

Authors:  L Bigornia; K M Lockridge; E E Sparger
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.

Authors:  Robert White; Nicole Chenciner; Gregory Bonello; Mary Salas; Philippe Blancou; Marie-Claire Gauduin
Journal:  Vaccine       Date:  2013-11-25       Impact factor: 3.641

8.  Selective infection of human T-lymphotropic virus type 1 (HTLV-1)-infected cells by chimeric human immunodeficiency viruses containing HTLV-1 tax response elements in the long terminal repeat.

Authors:  H C Lin; M Bodkin; R B Lal; A B Rabson
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1.

Authors:  B Majello; P De Luca; G Hagen; G Suske; L Lania
Journal:  Nucleic Acids Res       Date:  1994-11-25       Impact factor: 16.971

10.  Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains.

Authors:  B Berkhout; K Verhoef; J L van Wamel; N K Back
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.